Belvedere Trading
KYNB

Belvedere Trading’s Kyntra Bio KYNB Stock Holding History

Belvedere Trading’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,041
Closed -$120K – 772
2024
Q1 		$120K Buy
+2,041
New +$87.9K ﹤0.01% 405

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Belvedere Trading's KYNB Position: Q2 2024 in Review

Belvedere Trading sold out of Kyntra Bio (KYNB) in Q2 2024, closing a stake of 2,041 shares — an estimated $120K sold.

Belvedere Trading first reported a position in KYNB in Q1 2024 and held it in 1 quarter. The position peaked at $120K in Q1 2024. 102 funds tracked by Wall St. Rank hold KYNB as of Q2 2024.

  • Belvedere Trading reported no remaining Kyntra Bio position as of Q2 2024 after selling out during the quarter.
  • Belvedere Trading sold 2,041 Kyntra Bio shares in Q2 2024, an estimated $120K.
  • Belvedere Trading first reported a position in Kyntra Bio in Q1 2024 and held it in 1 quarter.
  • Belvedere Trading's Kyntra Bio position peaked at $120K in Q1 2024.
  • 102 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2024.

Based on Belvedere Trading's 13F filing for Q2 2024, filed 9 Aug 2024.